Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Sleepwalking and Sleep Talking01:17

Sleepwalking and Sleep Talking

Somnambulism, commonly known as sleepwalking, involves individuals engaging in activities ranging from simple walking to more complex behaviors such as driving. Sleepwalking typically occurs during the slow-wave sleep stages 3 and 4 early in the night when the person is not dreaming, contradicting the myth that sleepwalkers are acting out their dreams.
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NKG2A and NKp30 expression in NK cells correlates with preserved white matter and cortical thickness and reduced negative symptoms in psychiatric disorders.

Journal of affective disorders·2026
Same author

Development of a 3D tumor model based on decellularized matrix using high-throughput approaches.

Frontiers in bioengineering and biotechnology·2026
Same author

Exploring the impact of age, sex and life experiences on plasma inflammatory profiles through comparative proteomics.

Frontiers in immunology·2026
Same author

CD2 targeted nanoparticles containing IL-2 mimic fetal-maternal tolerance of pregnancy by inducing synergistic TGF-β-producing NK cells and Tregs.

Frontiers in immunology·2025
Same author

An early-stage 3D fibroblast-featured tumor model mimics the gene expression of the naïve tumor microenvironment, including genes involved in cancer progression and drug resistance.

Frontiers in oncology·2025
Same author

Peripheral and central innate immune alterations in schizophrenia and bipolar disorder: a systematic review of NK cells, monocytes and macrophages.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2025

Related Experiment Video

Updated: Jun 27, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

New therapies in SLE.

Francesca Ferrera1, Gilberto Filaci, Marta Rizzi

  • 1Centre of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.

Recent Patents on Inflammation & Allergy Drug Discovery
|December 17, 2008
PubMed
Summary
This summary is machine-generated.

Systemic lupus erythematosus (SLE) therapy is complex due to diverse symptoms and immune issues. This review updates on novel drugs, compounds, and recent patents showing therapeutic promise for SLE management.

More Related Videos

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
06:23

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice

Published on: September 22, 2020

Related Experiment Videos

Last Updated: Jun 27, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
06:23

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice

Published on: September 22, 2020

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) is a complex autoimmune disease with varied manifestations and immune dysregulation.
  • Current SLE therapies face challenges due to disease heterogeneity and intricate immune abnormalities.

Purpose of the Study:

  • To review recent advancements in systemic lupus erythematosus (SLE) therapeutics.
  • To highlight novel drugs, compounds, and emerging patents for SLE management.

Main Methods:

  • Literature review of preclinical studies and clinical trials.
  • Analysis of recent patents related to SLE therapeutics.
  • Synthesis of current knowledge on new therapeutic approaches.

Main Results:

  • Preclinical studies demonstrate the efficacy of several new drugs and compounds for SLE.
  • Clinical trials are evaluating some of these novel therapeutic agents.
  • Recent patents indicate potential for future SLE treatment innovations.

Conclusions:

  • Emerging therapies show promise for improving systemic lupus erythematosus (SLE) management.
  • Novel compounds and patented treatments may expand the clinical armamentarium for SLE.
  • Continued research and development are crucial for advancing SLE therapy.